Skip to main content
Announcements

Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business

November 4, 2024

Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.

The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).

連絡先

Belke, Daniel J.
パートナー
Hofheimer, Joshua T.
パートナー
Grau, Lauren G.
パートナー
Glavota, Sabrina K.
Managing Associate

得意分野

Suggested News & Insights

Sidley Earns Three Finalist Recognitions in The American Lawyer Industry Awards 2026August 17, 2026
Accolades
U.S. FinCEN Issues Final Rule Ending Beneficial Ownership Reporting RequirementAugust 14, 2026
White Collar Defense and Investigations Update
Sidley Represents Board of Directors of Accelerant in US$4 Billion Acquisition by Thoma BravoAugust 13, 2026
Announcements
Concessions and Particularity: How a Derivative Challenge to a Discounted Insider Financing Failed at the Pleading StageAugust 11, 2026
Enhanced Scrutiny
Sidley Represents Acteon in the Sale of Menck to CadelerAugust 11, 2026
Announcements
Sidley Represents Goldman Sachs Alternatives in Acquisition of Tosca From Apax FundsAugust 11, 2026
Announcements